|
Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis |
Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK. Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion 2012; 52(11): 2375-2381 Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Anti-HIV Agents /economics /therapeutic use; Blood Component Removal /economics; Cost-Benefit Analysis; Drug Costs; Female; Granulocyte Colony-Stimulating Factor /economics /therapeutic use; Hematopoietic Stem Cell Mobilization /economics /methods; Heterocyclic Compounds /economics /therapeutic use; Humans; Lymphoma /drug therapy /economics; Male; Middle Aged; Multiple Myeloma /drug therapy /economics; Recombinant Proteins /economics /therapeutic use; Retrospective Studies; Treatment Outcome AccessionNumber 22012044230 Date bibliographic record published 18/02/2013 |
|
|
|